Multicenter, randomized cross-control study to evaluate the efficacy of low-frequency and high-frequency deep brain stimulation in the treatment of drug-refractory partial epilepsy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023842

Enrollment

Unknown

Registered

2019-06-14

Start date

2019-07-01

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

partial epilepsy

Interventions

1:LFS first, then HFS

2:HFS first, then LFS

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 65 years; 2) Regular use of two or more antiepileptic drugs to achieve the optimal drug dosage, but epilepsy still does not alleviate, the number of seizures is still 2 times/month or more; 3) Patients with partial seizures of epilepsy, including secondary tonic-clonic epilepsy (sGTCS); 4) After strict preoperative evaluation, those who are still unable to undergo excisional surgery or who have poor expectations of excisional surgery are still unable to do so; 5) The patient or his family members can fully understand the treatment and sign the informed consent; 6) The patients have good compliance and can cooperate with the requirements of follow-up after operation.

Exclusion criteria

Exclusion criteria: 1) Those who take antiepileptic drugs irregularly to reach the best dosage of drug treatment; 2) IQ < 70; 3) There are mental, cognitive and psychological disorders, unable to sign informed consent or cooperate with surgery and follow-up; 4) There are contraindications of neurosurgery, such as cerebral infarction, hydrocephalus, brain atrophy, ventricular enlargement, sequelae of cerebrovascular disease, heart disease, severe thrombocytopenia and other cardiovascular and cerebrovascular diseases; 5) There are other concomitant diseases, such as pacemaker, defibrillator, cochlear implant, etc.; 6) There are concomitant diseases that seriously affect health, such as tumors, severe abnormalities of liver function and kidney function (indicators exceeding three times the normal value).

Design outcomes

Primary

Measure	Time frame
seizure frequency;	—

Secondary

Measure	Time frame
Severity of epilepsy;quality of life;	—

Countries

China

Contacts

Public ContactZhang Kai

Beijing Tiantan Hospital, Capital Medical University

zhangkai62035@163.com+86 13501196619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026